FI3880660T3 - Yhdisteitä ja koostumuksia nlrp-aktiivisuuteen liittyvien tilojen hoitamiseksi - Google Patents

Yhdisteitä ja koostumuksia nlrp-aktiivisuuteen liittyvien tilojen hoitamiseksi

Info

Publication number
FI3880660T3
FI3880660T3 FIEP19817831.1T FI19817831T FI3880660T3 FI 3880660 T3 FI3880660 T3 FI 3880660T3 FI 19817831 T FI19817831 T FI 19817831T FI 3880660 T3 FI3880660 T3 FI 3880660T3
Authority
FI
Finland
Prior art keywords
aaa
akaa
hon
aaa aaa
yhdiste
Prior art date
Application number
FIEP19817831.1T
Other languages
English (en)
Finnish (fi)
Inventor
Shomir Ghosh
Gary Glick
Jason Katz
William Roush
Hans Seidel
Dong-Ming Shen
Shankar Venkatraman
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Application granted granted Critical
Publication of FI3880660T3 publication Critical patent/FI3880660T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
FIEP19817831.1T 2018-11-13 2019-11-11 Yhdisteitä ja koostumuksia nlrp-aktiivisuuteen liittyvien tilojen hoitamiseksi FI3880660T3 (fi)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US201862760209P 2018-11-13 2018-11-13
US201862760248P 2018-11-13 2018-11-13
US201862760244P 2018-11-13 2018-11-13
US201862768811P 2018-11-16 2018-11-16
US201862769165P 2018-11-19 2018-11-19
US201862769151P 2018-11-19 2018-11-19
US201962795919P 2019-01-23 2019-01-23
US201962796356P 2019-01-24 2019-01-24
US201962796361P 2019-01-24 2019-01-24
US201962836585P 2019-04-19 2019-04-19
US201962836577P 2019-04-19 2019-04-19
US201962836575P 2019-04-19 2019-04-19
US201962895595P 2019-09-04 2019-09-04
PCT/US2019/060770 WO2020102096A1 (en) 2018-11-13 2019-11-11 Compounds and compositions for treating conditions associated with nlrp activity

Publications (1)

Publication Number Publication Date
FI3880660T3 true FI3880660T3 (fi) 2025-10-02

Family

ID=68841175

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19817831.1T FI3880660T3 (fi) 2018-11-13 2019-11-11 Yhdisteitä ja koostumuksia nlrp-aktiivisuuteen liittyvien tilojen hoitamiseksi

Country Status (31)

Country Link
US (1) US20230031406A1 (https=)
EP (2) EP3880660B1 (https=)
JP (2) JP7730759B2 (https=)
KR (1) KR20210096123A (https=)
CN (2) CN113166065B (https=)
AU (1) AU2019379109B2 (https=)
BR (1) BR112021008969A2 (https=)
CA (1) CA3114918A1 (https=)
CL (1) CL2021001228A1 (https=)
CO (1) CO2021006075A2 (https=)
CR (1) CR20210235A (https=)
DK (1) DK3880660T3 (https=)
EC (2) ECSP21033236A (https=)
ES (1) ES3042546T3 (https=)
FI (1) FI3880660T3 (https=)
HR (1) HRP20251344T1 (https=)
HU (1) HUE073575T2 (https=)
IL (1) IL283042B2 (https=)
JO (1) JOP20210105B1 (https=)
LT (1) LT3880660T (https=)
MA (1) MA54229B1 (https=)
MX (1) MX2021005529A (https=)
MY (1) MY206733A (https=)
PE (1) PE20211698A1 (https=)
PH (1) PH12021500025A1 (https=)
PL (1) PL3880660T3 (https=)
PT (1) PT3880660T (https=)
RS (1) RS67257B1 (https=)
SG (1) SG11202103405TA (https=)
SI (1) SI3880660T1 (https=)
WO (1) WO2020102096A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11370776B2 (en) * 2017-07-07 2022-06-28 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
WO2019034693A1 (en) 2017-08-15 2019-02-21 Inflazome Limited SULFONYLURATES AND SULFONYLTHIOURES AS INHIBITORS OF NLRP3
MX2020001776A (es) 2017-08-15 2020-03-24 Inflazome Ltd Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3.
US11542255B2 (en) 2017-08-15 2023-01-03 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
US12221434B2 (en) 2017-11-09 2025-02-11 Inflazome Limited Sulfonamide carboxamide compounds
KR20200087759A (ko) 2017-11-09 2020-07-21 인플라좀 리미티드 신규한 설폰아마이드 카복스아마이드 화합물
EP3759077A1 (en) 2018-03-02 2021-01-06 Inflazome Limited Novel compounds
EP3823974A1 (en) 2018-07-20 2021-05-26 F. Hoffmann-La Roche AG Sulfonimidamide compounds as inhibitors of interleukin-1 activity
CN117105890A (zh) * 2019-11-12 2023-11-24 成都百裕制药股份有限公司 酰胺衍生物及其制备方法和在医药上的应用
EP4093509A1 (en) * 2020-01-22 2022-11-30 F. Hoffmann-La Roche AG Sulfonimidamide compounds as nlrp3 modulators
WO2022023907A1 (en) 2020-07-31 2022-02-03 Novartis Ag Methods of selecting and treating patients at elevated risk of major adverse cardiac events
JP7825294B2 (ja) * 2021-02-10 2026-03-06 ハンジョウ イノゲート ファーマ カンパニー リミテッド Ｎｌｒｐ３阻害剤としての化合物
US11932630B2 (en) 2021-04-16 2024-03-19 Novartis Ag Heteroaryl aminopropanol derivatives
CN116635374B (zh) * 2021-05-10 2025-05-06 康百达（四川）生物医药科技有限公司 酰胺衍生物及其应用
WO2022237782A1 (zh) * 2021-05-10 2022-11-17 成都百裕制药股份有限公司 酰胺衍生物及其应用
TWI815439B (zh) * 2021-05-10 2023-09-11 大陸商成都百裕製藥股份有限公司 醯胺衍生物及其應用
CN114989058B (zh) * 2022-06-02 2024-04-16 中国科学院成都生物研究所 一种手性氯代砜亚胺类化合物及其衍生物的制备方法
CN115974745B (zh) * 2022-12-27 2025-06-03 瑞石生物医药有限公司 一类含引达省的化合物及其医药用途
CN116253664A (zh) * 2023-02-01 2023-06-13 山东海科创新研究院有限公司 基于双液相微乳化缩合工艺的accp制备方法
WO2025153532A1 (en) 2024-01-16 2025-07-24 NodThera Limited Nlrp3 inhibitors and glp-1 agonists combination therapies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102727059B1 (ko) * 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
US11597706B2 (en) * 2016-04-18 2023-03-07 Novartis Ag Compounds and compositions for treating conditions associated with NLRP activity
RS65492B1 (sr) * 2017-07-24 2024-05-31 Novartis Ag Jedinjenja i kompozicije za lečenje stanja povezanih sa aktivnošću nlrp
CN111094242B (zh) * 2017-07-24 2024-02-09 诺华股份有限公司 用于治疗与nlrp活性相关的病症的化合物和组合物
EP3823974A1 (en) * 2018-07-20 2021-05-26 F. Hoffmann-La Roche AG Sulfonimidamide compounds as inhibitors of interleukin-1 activity

Also Published As

Publication number Publication date
RS67257B1 (sr) 2025-10-31
PH12021500025A1 (en) 2022-05-02
AU2019379109A1 (en) 2021-05-06
CN113166065B (zh) 2025-04-15
ECSP24044340A (es) 2024-07-31
ES3042546T3 (en) 2025-11-21
ECSP21033236A (es) 2021-06-30
KR20210096123A (ko) 2021-08-04
JOP20210105A1 (ar) 2023-01-30
MX2021005529A (es) 2021-06-18
CN113166065A (zh) 2021-07-23
DK3880660T3 (da) 2025-10-06
IL283042B1 (en) 2024-08-01
CN120531732A (zh) 2025-08-26
LT3880660T (lt) 2025-10-10
IL283042A (en) 2021-06-30
PE20211698A1 (es) 2021-09-01
BR112021008969A2 (pt) 2021-08-03
CO2021006075A2 (es) 2021-05-31
MA54229B1 (fr) 2025-09-30
JP7730759B2 (ja) 2025-08-28
TW202031647A (zh) 2020-09-01
CR20210235A (es) 2021-06-30
SI3880660T1 (sl) 2025-11-28
JP2022507065A (ja) 2022-01-18
CL2021001228A1 (es) 2021-12-31
JOP20210105B1 (ar) 2024-12-22
EP3880660B1 (en) 2025-07-02
MY206733A (en) 2025-01-03
CA3114918A1 (en) 2020-05-22
PT3880660T (pt) 2025-10-21
HRP20251344T1 (hr) 2025-12-19
EP4667054A2 (en) 2025-12-24
MA54229A (fr) 2022-02-16
SG11202103405TA (en) 2021-05-28
JP2024113083A (ja) 2024-08-21
IL283042B2 (en) 2024-12-01
HUE073575T2 (hu) 2026-01-28
EP4667054A3 (en) 2026-02-18
WO2020102096A1 (en) 2020-05-22
EP3880660A1 (en) 2021-09-22
AU2019379109B2 (en) 2022-07-07
PL3880660T3 (pl) 2025-11-12
US20230031406A1 (en) 2023-02-02

Similar Documents

Publication Publication Date Title
FI3880660T3 (fi) Yhdisteitä ja koostumuksia nlrp-aktiivisuuteen liittyvien tilojen hoitamiseksi
Raza et al. Harnessing metabolomics for enhanced crop drought tolerance
Marshall et al. Potential for climate change driven spatial mismatches between apple crops and their wild bee pollinators at a continental scale
WILDAN Kajian Terhadap Pembangunan Geotermal Di Pulau Flores Berdasarkan Prespektif Teori Keadilan (John Rawls)
Wang et al. Research on Combat Effectiveness Based on Internet of Things
Alexiev The War in Afghanistan: Soviet Strategy and the State of the Resistance
CN203772861U (zh) 一种盐碱地土壤ph值及盐离子监测仪
Syamiajaya OPTIMALISASI DISLOKASI PASUKAN KODAM XII/TANJUNGPURA DALAM MENGHADAPI POTENSI ANCAMAN GENCATAN SENJATA BERSENJATA MELALUI KECEPATAN PERGERAKAN DAN PENGERAHAN PASUKAN DI WILAYAH PERBATASAN KALIMANTAN BARAT SEKTOR BARAT DENGAN BERKOLABORASI BERSAMA SATUAN TUGAS PENGAMANAN PERBATASAN REPUBLIK INDONESIA-MALAYSIA
Muraru A critical analysis of sense and avoid technologies for modern UAVs
CN205239898U (zh) 一种多重加密控制的无人机
DUDNYK et al. RECOGNITION OF ORGANIC CAMOUFLAGE USING NEURAL NETWORKS
Keith et al. The fate of an engineered planet
Marangon et al. Spectroscopical characterization of chitin extracted from different BSF sources
Clery Low-cost array hunts radio bursts, black holes
De Luca et al. COSMO-SkyMed dual-use and multi-national experienced challenges and operational implications
Imada Detecting diversity and seasonality of bryophyte-arthropod interactions
Trapani et al. From Cnidarian immunobiology to cultural heritage applications
Nailyevna et al. THE INFLUENCE OF THE ADF ON EMERGING TRENDS IN THE GLOBAL ARMS MARKET
Liu et al. Research on the Construction of Command and Control System for Multi Domain Parallel Operations
Rudko THE DANISH MODEL OF MILITARY ASSISTANCE TO UKRAINE AS AN EXPRESSION OF A NEW SECURITY DIPLOMACY IN INTERNATIONAL RELATIONS
Ehrenburg et al. CS-R9458 1994
D'Errico et al. Earth Observation with MEO Transmitters and UAS Receivers: a potential implementation for future Galileo upgrades
Neskorodev BENDING OF TRANSVERSAL-ISOTROPIC VISCOELASTIC PLATES IN THE IMPROVED THEORY
Nikishin THE CONCEPT OF MULTIDOMAIN BATTLE AS A MILITARY PARADIGM OF THE 21ST CENTURY
Kuba The cephalopod specialties: Complex nervous system, learning, and cognition